• Pharma
  • June 6, 2025
  • 301 views
Wockhardt’s novel antibiotic Zaynich eyes $9 billion global market

Mumbai-based pharma major Wockhardt, which is all set to launch its new class of antibiotic Zaynich targeted at treating complicated gram-negative infections in India this year, estimates that the drug…

  • Pharma
  • May 9, 2025
  • 254 views
Biocon Q4 net profit surges 153%, biosimilars, generics drive growth

Biocon, India’s leading biopharmaceutical company, reported a 153 percent year-on-year (YoY) jump in net profit for the fourth quarter of FY25, led by strong performances in its biosimilars and generics…

  • Pharma
  • May 1, 2019
  • 214 views
Biocon Bets Fired On Biosimilar For Revenue Growth

Searing growth in its biosimilar business is expected to help see Biocon cross $1 billion in revenue this fiscal. Biosimilars, or biologics, are biological drugs that are developed to be…